You are here: Industry Insights > ViiV

News List

GSK's long-acting HIV injectable hits FDA snag fiercepharma
December 27, 2019
HIV patients looking for relief from the burden of daily pills will have to wait a little longer.GlaxoSmithKline’s ViiV Healthcare said that the FDA had rejected its long-acting HIV injection ...
ViiV Healthcare seeks approval for child-friendly HIV treatment pharmaceutical-technology
December 17, 2019
ViiV Healthcare has submitted applications seeking approval from US and European regulators for a 5mg dispersible-tablet (DT) formulation of its dolutegravir (DTG) drug to treat children with ...
HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey fiercepharma
April 21, 2019
Pharma’s reputation is holding steady. That’s according to the annual patient group opinion report from PatientView……
ViiV’s two-drug regimen Dovato gets FDA approval for HIV-1 pharmaceutical-technology
April 11, 2019
ViiV’s two-drug regimen Dovato gets FDA approval for HIV-1.
ViiV builds case for long-acting HIV doublet firstwordpharma
March 15, 2019
Gilead Sciences has maintained its dominant position in the HIV marketplace thanks to a new generation of safer triplet drugs but ViiV Healthcare revealed more Phase III results suggesting that a long-acting injectable doublet may be able to elbow out a s
ViiV’s fostemsavir shows promise in ‘heavily pre-treated’ HIV patients pharmatimes
November 05, 2018
ViiV Healthcare’s first-in-class attachment inhibitor fostemsavir has shown promise as a treatment for heavily pre-treated HIV patients failing on...
US filing for ViiV’s two-drug, single pill HIV treatment pharmatimes
November 01, 2018
ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV...
ViiV submits two-drug regimen for HIV in Europe pharmatimes
September 18, 2018
ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine...
Janssen and ViiV report positive results for two drug regimen for HIV-1 pharmaceutical-technology
August 17, 2018
Johnson & Johnson subsidiary Janseen Pharmaceuticals and ViiV Healthcare have reported positive topline results from their phase III trial of an investigational long-acting injectable two drug regimen for the treatment of human immunodeficiency virus-1 (H
Janssen and ViiV's monthly injectable HIV combo proves non-inferior to daily standard of care pharmafile
August 16, 2018
Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, for the treatment of HIV-1, demonstrating similar efficacy to a standard daily, oral three-drug regimen over a 48 week period, meeting

Previous page 1 2 3 Next page